Frontierby eninvs

Language: EN · RU

← Region

AbbVie Inc. USD

At a glance: strengths & risks
✓Revenue growing (+9%)✓Margins improving (31%→38%)

Sector: Health care

US_ABBV

Price chart

249.46 USDDay -0.54%

Key metrics

Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.

Market

Price
249.46 USD · -0.54%
Market cap
442.3 bn USD

Growth

Δ revenue y/y
10.2%
Δ EBITDA y/y
-5.1%

Multiples

P/E (LTM)
70.1x
3y avg: 75.3x
P/B (FY)
—
P/E (ann.)
30.6x
EV/EBITDA (LTM)
21.6x
3y avg: 18.6x
EV/EBITDA (ann.)
18.8x

Cash return

Dividend yield
2.7%
FCF yield (LTM)
4.2%

Value creation

fundamental value/yr, % of market cap
Value created / year
-1.8%
↓ details

Liquidity

Daily turnover (US listing)
994.7 mln USD

Shares: yahoo_fundamentals_timeseries/ABBV

Financial results

Monetary columns are in B USD, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.

DatePeriodStatusRevenueB USDOperating profitB USDD&AB USDEBITDAB USDNet profitB USDOperating CFB USDCapex + M&AB USDAssetsB USDEquityB USDROE (annualized)Net debtB USDSource
2026-06-30Q2 2026 (3M)OK17.0
y/y 10.2%
6.4
y/y 31.4%
0.2
y/y -90.7%
6.6
y/y -5.1%
3.6
y/y 285.2%
3.4-0.3135.1
y/y -1.5%
5.9
y/y —
-4008.9%55.9—
2026-03-31Q1 2026 (3M)OK15.0
y/y 12.4%
4.0
y/y 6.9%
1.9
y/y -5.1%
5.9
y/y 2.7%
0.7
y/y -46.0%
3.8-0.3136.5
y/y 0.2%
-6.7
y/y -568.7%
-56.0%55.1Link
2025-12-31Q4 2025 (3M)OK16.6
y/y 10.0%
4.5
y/y 405.0%
1.9
y/y -10.1%
6.5
y/y 899.4%
1.8
y/y 8354.5%
5.2-0.3134.0
y/y -0.9%
-3.3
y/y -198.3%
-143.0%57.1Link
2025-09-30Q3 2025 (3M)OK15.8
y/y 9.1%
1.9
y/y -50.3%
2.1
y/y 0.0%
4.0
y/y -32.5%
0.2
y/y -88.1%
7.0-0.4133.9
y/y -6.6%
-2.6
y/y -143.8%
-17.6%61.1Link
2025-06-30Q2 2025 (3M)OK15.4
y/y 6.6%
4.9
y/y 22.4%
2.1
y/y 0.1%
7.0
y/y 14.8%
0.9
y/y -31.5%
5.2-0.3137.2
y/y -3.4%
-0.2
y/y -102.7%
606.6%62.0Link
2025-03-31Q1 2025 (3M)OK13.3
y/y 8.4%
3.7
y/y 33.4%
2.0
y/y -1.7%
5.8
y/y 18.5%
1.3
y/y -6.1%
1.6-0.4136.2
y/y -8.5%
1.4
y/y -82.3%
216.8%60.9Link
2024-12-31Q4 2024 (3M)OK15.1
y/y 5.6%
-1.5
y/y -146.6%
2.1
y/y 2.5%
0.6
y/y -87.7%
0.0
y/y -102.7%
7.0-0.3135.2
y/y 0.3%
3.3
y/y -67.9%
91.4%55.7Link
2024-09-30Q3 2024 (3M)OK14.5
y/y 3.8%
3.8
y/y 68.0%
2.1
y/y -4.8%
5.9
y/y 32.3%
1.6
y/y -12.2%
5.4-8.5143.4
y/y 5.3%
6.0
y/y -50.1%
32.5%51.2Link
2024-06-30Q2 2024 (3M)OK14.5
y/y 4.3%
4.0
y/y -11.4%
2.1
y/y -9.0%
6.1
y/y -10.6%
1.4
y/y -32.3%
2.3-0.2141.9
y/y 4.9%
6.8
y/y -47.3%
74.1%44.9Link
2024-03-31Q1 2024 (3M)OK12.3
y/y 0.7%
2.8
y/y 1.1%
2.1
y/y -2.5%
4.9
y/y -0.5%
1.4
y/y 472.8%
4.0-9.4148.9
y/y 10.7%
8.0
y/y -39.7%
59.6%45.7Link
2023-12-31Q4 2023 (3M)OK14.3
y/y —
3.2
y/y —
2.1
y/y —
5.3
y/y —
0.8
y/y —
4.8-0.2134.7
y/y —
10.4
y/y —
43.3%40.3Link
2023-09-30Q3 2023 (3M)OK13.9
y/y —
2.3
y/y —
2.2
y/y —
4.5
y/y —
1.8
y/y —
7.6-0.2136.2
y/y —
12.1
y/y —
19.0%42.3Link
2023-06-30Q2 2023 (3M)OK13.9
y/y —
4.5
y/y —
2.3
y/y —
6.8
y/y —
2.0
y/y —
6.3-0.2135.4
y/y —
12.9
y/y —
61.9%47.0Link
2023-03-31Q1 2023 (3M)OK12.2
y/y —
2.8
y/y —
2.1
y/y —
4.9
y/y —
0.2
y/y —
4.2-0.2134.5
y/y —
13.3
y/y —
—52.6Link

Net debt structure (leases included, IFRS 16) 2026-06-30

Long-term debt (incl. LT leases)62 481
− Cash & equivalents6 569
Net debt55 912

Net debt / LTM EBITDA: 2.4x

Revenue & EBITDA

RevenueEBITDA

Quarterly values ($ mln)

05 00010 00015 0002024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q2

Year-over-year change

-100%-50%0%50%2024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q2

Cash flow

FCF ($ mln)

-7 500-5 000-2 50002 5005 0002024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q2

Net debt / cash ($ mln)

020 00040 00060 0002024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q2

Profit and cash

Worth a look
In a typical year of 2021–2025 operating cash flow came to 4.40x of reported net profit; after capex, 4.17x.
year20212022202320242025
cash flow / profit1.97x2.11x4.70x4.40x4.50x
accruals, % of assets-7.7%-9.4%-13.3%-10.8%-11.1%
Last twelve months (to 2025-Q3): 3.09x of profit came back as operating cash flow.
net debt / EBITDA 2.5x · EBIT covers interest 5.2x · capex 0.1x of depreciation · dividends 51% of free cash flow
● Capex is 11% of depreciation - the asset base is being consumed faster than replaced.
Read from the reported annual statements: cash flow / profit is the median of the yearly operating cash flow over net profit for the years shown; accruals are (profit − operating cash flow) / assets, the classic gap between what was booked and what was collected. A gap can be growth in working capital, capitalised costs, revaluations or profit from associates — the panel points at it, the statements explain it. Not investment advice.

Fundamental value creation

Value the company creates per year, as a % of market cap

Value created per year: -1.8%

How this was calculated
1. EBITDA growth (latest quarter YoY, annualised)
[EBITDA latest qtr − EBITDA year-ago qtr] × annualisation X (2026-06-30 vs 2025-06-30)
= (6 626 − 6 980) × 3.48
-1 233
2. Current EV/EBITDA (LTM)
(Market cap + Net debt) ÷ EBITDA (LTM)
= (442 293 + 55 912) ÷ 23 079
21.6x
3. Target multiple
(Current EV/EBITDA + 12) ÷ 2
= (21.6 + 12) ÷ 2
16.8x
4. Cash flow (balance method, LTM)
Net-debt reduction + dividends + buybacks − equity issuance
= 6 136 + 5 997 + 1 493 − 0
13 626
4b. Share dilution (at market, LTM)
Share-count growth over the year × Market cap
= 0.2% × 442 293
−749
5. Value created per year
(EBITDA growth × Target multiple + Cash flow − Dilution) ÷ Market cap
= (-1 233 × 16.8 + 13 626 − 749) ÷ 442 293
-1.8%

Amounts in millions of the reporting currency. EBITDA growth is the latest quarter vs the same quarter a year ago, annualised.

Caveats:

  • share-count dilution 0.2%/yr (valued at market: -749)

Revenue growth & acceleration

Growth accelerating ▲
Last-year revenue growth +9% vs +4% the year before — a +4.9 pp move. 3-year CAGR +2%.
revenue growth by year: 2023 -6% · 2024 +4% · 2025 +9%
The growth-acceleration signal behind the GARP+acceleration strategy — it favours companies whose revenue growth is speeding up and flags those slowing down (the second derivative of growth).

EV/EBITDA — daily history

Current 21.5x · 3-year average 21.4x

EV/EBITDA3-year 75th pct

Dividends

Paid (completed)

DatePer shareDetailsStatusSource
2026-07-151.73 USDEx-dividend: 1.73 USD per sharePaidYahoo Finance (ex-div)
2026-04-151.73 USDEx-dividend: 1.73 USD per sharePaidYahoo Finance (ex-div)
2026-01-161.73 USDEx-dividend: 1.73 USD per sharePaidYahoo Finance (ex-div)
2025-10-151.64 USDEx-dividend: 1.64 USD per sharePaidYahoo Finance (ex-div)
2025-07-151.64 USDEx-dividend: 1.64 USD per sharePaidYahoo Finance (ex-div)
2025-04-151.64 USDEx-dividend: 1.64 USD per sharePaidYahoo Finance (ex-div)
2025-01-151.64 USDEx-dividend: 1.64 USD per sharePaidYahoo Finance (ex-div)
2024-10-151.55 USDEx-dividend: 1.55 USD per sharePaidYahoo Finance (ex-div)
2024-07-151.55 USDEx-dividend: 1.55 USD per sharePaidYahoo Finance (ex-div)
2024-04-121.55 USDEx-dividend: 1.55 USD per sharePaidYahoo Finance (ex-div)
2024-01-121.55 USDEx-dividend: 1.55 USD per sharePaidYahoo Finance (ex-div)
2023-10-121.48 USDEx-dividend: 1.48 USD per sharePaidYahoo Finance (ex-div)
2023-07-131.48 USDEx-dividend: 1.48 USD per sharePaidYahoo Finance (ex-div)
2023-04-131.48 USDEx-dividend: 1.48 USD per sharePaidYahoo Finance (ex-div)
2023-01-121.48 USDEx-dividend: 1.48 USD per sharePaidYahoo Finance (ex-div)
2022-10-131.41 USDEx-dividend: 1.41 USD per sharePaidYahoo Finance (ex-div)
2022-07-141.41 USDEx-dividend: 1.41 USD per sharePaidYahoo Finance (ex-div)
2022-04-131.41 USDEx-dividend: 1.41 USD per sharePaidYahoo Finance (ex-div)
2022-01-131.41 USDEx-dividend: 1.41 USD per sharePaidYahoo Finance (ex-div)
2021-10-141.3 USDEx-dividend: 1.3 USD per sharePaidYahoo Finance (ex-div)

KASE: status follows wording in the news headline (paid vs intends to pay). Yahoo: amounts are cash dividends per share on ex-dividend dates (UTC calendar date). stockscope.uz (UZ): amounts are per share in UZS by publication date (not necessarily ex-div).

Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)

Financial results, valuation multiples (P/E, P/B, EV/EBITDA), profitability and dividend yield of AbbVie Inc. — from primary filings.

Biopharmaceutical company focused on immunology, oncology, neuroscience, and aesthetics.

Frequently asked questions

What is AbbVie Inc.'s P/E ratio?
AbbVie Inc. trades at a P/E of 70.1x (price to trailing 12-month earnings).
What is AbbVie Inc.'s EV/EBITDA?
AbbVie Inc. trades at 21.6x EV/EBITDA.
What is AbbVie Inc.'s dividend yield?
AbbVie Inc.'s trailing 12-month dividend yield is 2.7%.
What is AbbVie Inc.'s return on equity (ROE)?
AbbVie Inc.'s ROE is -56.0%.
What is AbbVie Inc.'s market capitalization?
AbbVie Inc.'s market cap is 442.3 bn USD.

See also: The Cheapest Stocks in the World (2026): What Value Investing Says About Buying Cheap · global valuation map